364 related articles for article (PubMed ID: 28629371)
21. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
[TBL] [Abstract][Full Text] [Related]
23. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
[TBL] [Abstract][Full Text] [Related]
24. Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting.
Dadone-Montaudié B; Laroche-Clary A; Mongis A; Chamorey E; Mauro ID; Chaire V; Finetti P; Schiappa R; Le Loarer F; Birtwisle-Peyrottes I; Michiels JF; Bertucci F; Pedeutour F; Italiano A; Bianchini L
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092134
[TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
[TBL] [Abstract][Full Text] [Related]
27. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
28. CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Sriraman A; Dickmanns A; Najafova Z; Johnsen SA; Dobbelstein M
Cell Death Dis; 2018 Sep; 9(9):918. PubMed ID: 30206211
[TBL] [Abstract][Full Text] [Related]
29. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
[TBL] [Abstract][Full Text] [Related]
30. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
Phelps D; Bondra K; Seum S; Chronowski C; Leasure J; Kurmasheva RT; Middleton S; Wang D; Mo X; Houghton PJ
Pediatr Blood Cancer; 2015 Aug; 62(8):1345-52. PubMed ID: 25832557
[TBL] [Abstract][Full Text] [Related]
33. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
34. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
[TBL] [Abstract][Full Text] [Related]
35. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
[TBL] [Abstract][Full Text] [Related]
37. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyaki M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh AS; Chmielowski B; Nelson SD; Russell TA; Eckardt MA; Dry SM; Li Y; Singh SR; Chawla SP; Eilber FC; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2018 Dec; 506(4):912-917. PubMed ID: 30392912
[TBL] [Abstract][Full Text] [Related]
38. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract][Full Text] [Related]
39. Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma.
Avallone G; Roccabianca P; Crippa L; Lepri E; Brunetti B; Bernardini C; Forni M; Olandese A; Sarli G
Vet Pathol; 2016 Jul; 53(4):773-80. PubMed ID: 26993784
[TBL] [Abstract][Full Text] [Related]
40. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
Zhou Z; Zalutsky MR; Chitneni SK
Mol Pharm; 2021 Oct; 18(10):3871-3881. PubMed ID: 34523337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
